Market Research Logo

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)

The global Non-Alcoholic Steatohepatitis (NASH) drugs market is expected to reach US$61.60 billion in 2028, growing at a CAGR of 39.36%, for the duration spanning 2018-2028. The factors such as rising prevalence of NASH, increasing diabetic population, rising obesity, unmet medical needs and sedentary lifestyle are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD. A few notable trends include escalating market penetration for NASH major drugs, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in E-Commerce pharmaceutical products sales.

The global Non-Alcoholic Steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market in coming years, with considerable market share. The need for definitive NASH treatment would lead to strong market penetration of the therapeutic drugs during the forecasted period.

The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs. Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods.

Scope of the report:

  • The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.
  • The major regional markets (the U.S. and Europe) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.
Key Target Audience:
  • NAFLD/NASH Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities


1. Market Overview
1.1 Introduction
Table 1: NAFLD Spectrum and Estimated Advancement Risk
1.2 Causes & Symptoms
1.3 Diagnosis
1.4 Treatment
Table 2: Treatment of NASH
1.5 Off-Label Treatment
Table 3: NASH Off-Label Therapies
1.6 Therapeutic Treatment
Table 4: Potential Phase III NASH Drugs
2. Global NASH Market
2.1 Global NASH Drugs Market Forecast by Value
Table 5: Global NASH Drugs Market Forecast by Value (2018-2028)
2.2 Global NASH Drugs Market Value Forecast by Drug Class
Table 6: Global NASH Drugs Market Value Forecast by Drug Class (2018/2023/2028)
2.3 Global NASH Off-Label Drugs Market Forecast by Value
Table 7: Global NASH Off-Label Drugs Market Forecast by Value (2018-2028)
3. Global NASH Therapeutics Market
3.1 Global NASH Therapeutics Market Forecast by Value
Table 8: Global NASH Therapeutics Market Forecast by Value (2020-2028)
3.2 Global NASH Therapeutics Market Value Forecast by Drug Type
3.2.1 Global NASH Therapeutics Market Value Forecast by Drug Type (2023)
Table 9: Global NASH Therapeutics Market Value Forecast by Drug Type (2023)
3.2.2 Global NASH Therapeutics Market Value Forecast by Drug Type (2028)
Table 10: Global NASH Therapeutics Market Value Forecast by Drug Type (2028)
3.2.3 Global Obeticholic Acid (OCA) Drug Market Forecast by Value
Table 11: Global Obeticholic Acid (OCA) Drug Market Forecast by Value (2020-2028)
3.2.4 Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region
Table 12: Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region (2028)
3.2.5 Global Cenicriviroc (CVC) Drug Market Forecast by Value
Table 13: Global Cenicriviroc (CVC) Drug Market Forecast by Value (2020-2028)
3.2.6 Global Cenicriviroc (CVC) Drug Market Value Forecast by Region
Table 14: Global Cenicriviroc (CVC) Drug Market Value Forecast by Region (2028)
3.2.7 Global Elafibranor Drug Market Forecast by Value
Table 15: Global Elafibranor Drug Market Forecast by Value (2020-2028)
3.2.8 Global Aramchol Drug Market Forecast by Value
Table 16: Global Aramchol Drug Market Forecast by Value (2022-2028)
3.2.9 Global MGL-3196 Drug Market Forecast by Value
Table 17: Global MGL-3196 Drug Market Forecast by Value (2023-2028)
3.2.10 Global INN-217 Drug Market Forecast by Value
Table 18: Global INN-217 Drug Market Forecast by Value (2023-2028)
3.2.11 Global VK2809 Drug Market Forecast by Value
Table 19: Global VK2809 Drug Market Forecast by Value (2023-2028)
3.3 Global NASH Therapeutics Market Value Forecast by Region
3.3.1 Global NASH Therapeutics Market Value Forecast by Region (2023)
Table 20: Global NASH Therapeutics Market Value Forecast by Region (2023)
3.3.2 Global NASH Therapeutics Market Value Forecast by Region (2028)
Table 21: Global NASH Therapeutics Market Value Forecast by Region (2028)
4. Regional NASH Market
4.1 The U.S. NASH Therapeutics Market Forecast by Value
Table 22: The U.S. NASH Therapeutics Market Forecast by Value (2022-2028)
4.2 Europe NASH Therapeutics Market Forecast by Value
Table 23: Europe NASH Therapeutics Market Forecast by Value (2022-2028)
4.3 ROW NASH Therapeutics Market Forecast by Value
Table 24: ROW NASH Therapeutics Market Forecast by Value (2022-2028)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Prevalence of NASH
Table 25: The U.S. NASH Patient Population (2018-2028)
5.1.2 Rising HealthCare Expenditure
Table 26: Global HealthCare Expenditure Per Capita (2014-2018)
5.1.3 Increasing Diabetic Population
Table 27: Global Diabetic Population (2014-2018)
5.1.4 Rising Obesity
Table 28: Global Obese Patient Population (2014-2018)
5.1.5 Unmet Medical Needs
5.1.6 Sedentary Lifestyle
5.2 Key Trends & Development
5.2.1 Escalating Market Penetration for NASH Major Drugs
Table 29: Number of NASH Patients treated with Ocaliva and Selonsertib Forecast (2020-2025)
5.2.2 Increase in Pharmaceutical R&D Expenditures
Table 30: Global Pharmaceutical R&D Expenditures (2014-2018)
5.2.3 Progressing NASH Diagnosis Methods and Biomarkers
Table 31: Selected NASH Diagnosis Methods and Biomarkers under Development (2018)
5.2.4 NASH Pipeline Drugs under Development
Table 32: Drugs under Development for NASH (2018)
5.2.5 Growth in E-Commerce Pharmaceutical Products Sales
Table 33: Global E-Commerce Pharmaceutical Products Sales (2018-2023)
5.3 Challenges
5.3.1 Lethargic Drug Approval Process
Table 34: Drugs Approval Process
5.3.2 High Treatment Cost
Table 35: NASH Annual Treatment Cost Comparison (2018)
5.3.3 Associated Business Risk
5.3.4 Less Definitive Diagnostic Methods for NASH/NAFLD
6. Competitive Landscape
6.1 Global NASH Drugs Market
6.1.1 Key Players – Product Portfolio Comparison
Table 36: Key Players – Product Portfolio Comparison (2018)
6.1.2 Key Players – Phase II clinical trials in NASH with histological endpoints Comparison
Table 37: Key Players – Phase II clinical trials in NASH with histological endpoints Comparison
6.1.3 Key Players – R&D Comparison
Table 38: Key Players - R&D Comparison (2017-2018)
6.1.4 Key Players - Revenue Comparison
Table 39: Key Players - Revenue Comparison (2018)
6.1.5 Key Players – Market Cap Comparison
Table 40: Key Players - Market Cap Comparison (2019)
7. Company Profiles
7.1 Bristol Myers Squibb
7.1.1 Business Overview
7.1.2 Financial Overview
Table 41: Bristol Myers Squibb Total Revenue and Net Earnings (2014-2018)
Table 42: Bristol Myers Squibb Total Revenue by Segments (2018)
Table 43: Bristol Myers Squibb Total Revenue by Regions (2018)
7.1.3 Business Strategies
7.2 Gilead Sciences, Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
Table 44: Gilead Sciences Total Revenues and Net Income (2014-2018)
Table 45: Gilead Sciences Total Revenues by Business Segments (2018)
Table 46: Gilead Sciences Total Revenues by Regions (2018)
7.2.3 Business Strategies
7.3 Allergan Plc (Tobira)
7.3.1 Business Overview
7.3.2 Financial Overview
Table 47: Allergan Plc. (Tobira) Net Revenues and Net Loss (2014-2018)
Table 48: Allergan Plc. (Tobira) Net Revenues by Segments (2018)
Table 49: Allergan Plc. (Tobira) Net Revenues by Regions (2018)
7.3.3 Business Strategies
7.4 Intercept Pharmaceuticals, Inc.
7.4.1 Business Overview
Table 50: Intercept Pharmaceuticals Product Pipeline (2018)
7.4.2 Financial Overview
Table 51: Intercept Pharmaceuticals Revenue and Net Loss (2014-2018)
Table 52: Intercept Pharmaceuticals Revenue by Segments (2018)
7.4.3 Business Strategies
7.5 Galmed Pharmaceuticals
7.5.1 Business Overview
7.5.2 Financial Overview
Table 53: Galmed Pharmaceuticals Revenue and Net Loss (2014-2018)
7.5.3 Business Strategies
7.6 Genfit SA
7.6.1 Business Overview
Table 54: Genfit SA Product Pipeline (2018)
7.6.2 Financial Overview
Table 55: Genfit SA Revenue and Net Loss (2014-2018)
7.6.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report